For a Commentary on this article, please see Kanis et al. (J Bone Miner Res. 2014;29:1926–1928. DOI: 10.1002/jbmr.2301).
Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
Article first published online: 20 AUG 2014
© 2014 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Journal of Bone and Mineral Research
Volume 29, Issue 9, pages 1929–1937, September 2014
How to Cite
Solomon, D. H., Johnston, S. S., Boytsov, N. N., McMorrow, D., Lane, J. M. and Krohn, K. D. (2014), Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011. J Bone Miner Res, 29: 1929–1937. doi: 10.1002/jbmr.2202
- Issue published online: 20 AUG 2014
- Article first published online: 20 AUG 2014
- Accepted manuscript online: 18 FEB 2014 07:15AM EST
- Manuscript Accepted: 13 FEB 2014
- Manuscript Revised: 12 FEB 2014
- Manuscript Received: 20 DEC 2013
- Eli Lilly & Company
- TREATMENT PATTERNS;
- HIP FRACTURE
Hip fractures are common, morbid, costly, and associated with subsequent fractures. Historically, postfracture osteoporosis medication use rates have been poor, but have not been recently examined in a large-scale study. We conducted a retrospective, observational cohort study based on U.S. administrative insurance claims data for beneficiaries with commercial or Medicare supplemental health insurance. Eligible participants were hospitalized for hip fracture between January 1, 2002, and December 31, 2011, and aged 50 years or older at admission. The outcome of interest was osteoporosis medication use within 12 months after discharge. Patients were censored after 12 months, loss to follow-up, or a medical claim for cancer or Paget's disease, whichever event occurred first. During the study period, 96,887 beneficiaries met the inclusion criteria; they had a mean age of 80 years and 70% were female. A total of 34,389 (35.5%) patients were censored before reaching 12 months of follow-up. The Kaplan-Meier estimated probability of osteoporosis medication use within 12 months after discharge was 28.5%. The rates declined significantly from 40.2% in 2002, to 20.5% in 2011 (p for trend <0.001). In multivariable Cox proportional hazards models, a number of patient characteristics were associated with reduced likelihood of osteoporosis medication use, including older age and male gender. However, the predictor most strongly and most positively associated with osteoporosis medication use after fracture was osteoporosis medication use before the fracture (hazard ratio = 7.45; 95% confidence interval [CI], 7.23–7.69). Most patients suffering a hip fracture do not use osteoporosis medication in the subsequent year and treatment rates have worsened. © 2014 Eli Lilly and Company. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.